There are 1105 resources available
259P - Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study
Presenter: Jin Xu
Session: Poster Display session
Resources:
Abstract
260P - NALIRIFOX as subsequent therapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy: A real-world experience in single center
Presenter: Hisn-Chen Lin
Session: Poster Display session
Resources:
Abstract
261TiP - Randomized, open-label, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01
Presenter: Masafumi Ikeda
Session: Poster Display session
Resources:
Abstract
262TiP - Comparison of adjuvant chemoradiotherapy versus adjuvant chemotherapy in carcinoma gall bladder: A randomized controlled study
Presenter: Deepak Das
Session: Poster Display session
Resources:
Abstract
263TiP - TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)–directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Kohei Shitara
Session: Poster Display session
Resources:
Abstract
264TiP - A phase Ib/II open-label study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig and chemotherapy in patients with HER2-positive (HER2+) and HER2-low gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 Part 4
Presenter: Jeeyun Lee
Session: Poster Display session
Resources:
Abstract
265TiP - Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy 06B
Presenter: Ken Kato
Session: Poster Display session
Resources:
Abstract
266TiP - The efficacy of tislelizumab combined with S-1 in patients with residual primary lesions and node-negative esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy followed by curative resection: A phase II, multicenter trial (PPIO-008)
Presenter: Yingjian Wang
Session: Poster Display session
Resources:
Abstract
267TiP - CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor
Presenter: Wei Peng Yong
Session: Poster Display session
Resources:
Abstract
277P - Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase III CheckMate 901 trial
Presenter: Dingwei Ye
Session: Poster Display session
Resources:
Abstract